<DOC>
	<DOCNO>NCT00869713</DOCNO>
	<brief_summary>This study design determine safety immunogenicity inactivate Rift Valley Fever ( RVF ) Vaccine adult</brief_summary>
	<brief_title>Safety Immunogenicity Study Rift Valley Fever Vaccine , Inactivated</brief_title>
	<detailed_description>The primary objective assess safety Rift Valley Fever ( RVF ) Vaccine , Inactivated ( TSI-GSD 200 ) ass immunogenicity Rift Valley Fever ( RVF ) Vaccine , Inactivated ( TSI-GSD 200 ) . The secondary objective ass incidence RVF infection vaccinate personnel</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Coccidioidomycosis</mesh_term>
	<mesh_term>Coccidiosis</mesh_term>
	<mesh_term>Rift Valley Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . At least 18 year old . 2 . Females childbearing potential must negative serum urine pregnancy test within 48 hour vaccination . Females advise become pregnant 3 month primary series booster dose . 3 . Females must breastfeed . 4 . Subject must risk exposure RVF virus . 5 . Subject must uptodate ( within 1 year ) medical history , physical examination , laboratory test chart medically clear participation investigator . Examinations test qualify enrollment may repeat discretion investigator . 6 . Subject must sign date approve informed consent document . 7 . For initiation primary series , RVF PRNT80 &lt; 1:10 . 8 . For REENTRY protocol ROLLOVER earlier RVF protocol receive booster , RVF PRNT80 &lt; 1:40 within past 1 year 1 . Older 65 year age primary series vaccination ( able receive booster dos contraindication ) . 2 . Clinically significant abnormal lab result , include evidence Hepatitis C , Hepatitis B carrier state , elevate ( 2 time normal ) liver function test . 3 . Personal history immunodeficiency current treatment immunosuppressive medication . 4 . Confirmed positive human immunodeficiency virus ( HIV ) titer . 5 . Any medical condition , discretion physician , may jeopardize safety subject . 6 . Any serious lifethreatening allergy component vaccine : formalin human serum albumin neomycin streptomycin fetal rhesus lung cell RVF virus inactivate 7 . Administration Investigational New Drug ( IND ) product vaccine within 28 day RVF vaccination . 8 . Any unresolved adverse event result previous immunization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hemorrhagic Fever</keyword>
	<keyword>Viral Infections</keyword>
	<keyword>Neurologic disease</keyword>
	<keyword>Arbovirus Infections</keyword>
	<keyword>RVF</keyword>
</DOC>